Pre-clinical assessments of ONC201 in AML and MCL have led to further studies in panels of leukemia, lymphoma and MM cell lines, which have confirmed that the drug stimulates ISR activity as evidenced by the induction of ATF4 [75]. This evidence concerns the gene ATF4 and acute myeloid leukemia.